Zdrowie i gospodarka · 09/08/2021
FDA Announces Final Guidance on Metastasis-Free Survival Endpoint for Nonmetastatic Castration-Resistant Prostate Cancer Clinical Trials
The FDA is releasing a final guidance document outlining its expectations for collecting, analyzing, and reporting data on metastasis-free survival in clinical trials for patients with nonmetastatic castration-resistant prostate cancer, following recent approvals of several new treatments for the condition.